Cargando…

Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis

PURPOSE: This systematic review and meta-analysis aimed to evaluate the immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer. METHODS: We performed a systematic literature search using PubMed, Embase, and Cochrane Library until 28/09/2021, and conference proceedings from ASCO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martins-Branco, Diogo, Nader-Marta, Guilherme, Tecic Vuger, Ana, Debien, Veronique, Ameye, Lieveke, Brandão, Mariana, Punie, Kevin, Loizidou, Angela, Willard-Gallo, Karen, Spilleboudt, Chloe, Awada, Ahmad, Piccart, Martine, de Azambuja, Evandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304540/ https://www.ncbi.nlm.nih.gov/pubmed/35867203 http://dx.doi.org/10.1007/s00432-022-04185-w

Ejemplares similares

Antibody–drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment
por: Nader-Marta, Guilherme, et al.
Publicado: (2023)

HER2-Low Breast Cancer: Molecular Characteristics and Prognosis
por: Agostinetto, Elisa, et al.
Publicado: (2021)

PARIS score for evaluation of probability of SARS-CoV-2 infection in cancer patients
por: Gueuning, Candice, et al.
Publicado: (2022)

Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer
por: Ignatiadis, Michail, et al.
Publicado: (2016)

Risk factors for the development of brain metastases in patients with HER2-positive breast cancer
por: Maurer, Christian, et al.
Publicado: (2018)

Rapid hair depigmentation in patient treated with pazopanib
por: Šeparović, Robert, et al.
Publicado: (2018)

Anthracyclines in the treatment of early breast cancer friend or foe?
por: Vuger, Ana Tecic, et al.
Publicado: (2022)

Emerging issues related to COVID-19 vaccination in patients with cancer
por: Saini, Kamal S., et al.
Publicado: (2021)

Difference in Estimation of Side Effects of Chemotherapy between Physicians and Patients with Early-Stage Breast Cancer: The Use of Patient Reported Outcomes (PROs) in the Evaluation of Toxicity in Everyday Clinical Practice
por: Pavlović Mavić, Mirjana, et al.
Publicado: (2021)

Are we HER-ting for innovation in neoadjuvant breast cancer trial design?
por: Snoj, Natasa, et al.
Publicado: (2009)

UNCOMMON SIDE EFFECTS OF SUNITINIB THERAPY IN A PATIENT WITH METASTATIC RENAL CELL CANCER: CASE REPORT
por: Šeparović, Robert, et al.
Publicado: (2018)

OXALIPLATIN INDUCED PULMONARY FIBROSIS: A CASE REPORT
por: Pavlović, Mirjana, et al.
Publicado: (2020)

Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives
por: Caparica, Rafael, et al.
Publicado: (2019)

Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USA
por: Ades, Felipe, et al.
Publicado: (2017)

PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer
por: Agostinetto, Elisa, et al.
Publicado: (2022)

IMPACT OF BODY COMPOSITION ON THE QUALITY OF LIFE OF PREMENOPAUSAL PATIENTS WITH EARLY STAGE BREAST CANCER DURING CHEMOTHERAPY
por: Pavlović Mavić, Mirjana, et al.
Publicado: (2022)

SARS‐CoV‐2 infection in hematological patients during allogenic stem cell transplantation: A double case report
por: Alexandra, Van Uytvanck, et al.
Publicado: (2021)

Factors associated with SARS-CoV-2 infection and outcome in patients with solid tumors or hematological malignancies: a single-center study
por: Goudsmit, Anouk, et al.
Publicado: (2021)

ABCL-013: Factors Associated with SARS-CoV-2 Infection and Outcome in Patients with Solid Tumors or Hematological Malignancies: A Single-Center Study
por: Goudsmit, Anouk, et al.
Publicado: (2021)

Poster: ABCL-013: Factors Associated with SARS-CoV-2 Infection and Outcome in Patients with Solid Tumors or Hematological Malignancies: A Single-Center Study
por: Goudsmit, Anouk, et al.
Publicado: (2021)

FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer
por: Gombos, Andrea, et al.
Publicado: (2021)

Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer
por: Gombos, Andrea, et al.
Publicado: (2022)

Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis
por: Brandão, Mariana, et al.
Publicado: (2020)

Immunotherapy in breast cancer: an overview of current strategies and perspectives
por: Debien, Véronique, et al.
Publicado: (2023)

Post-Neoadjuvant Treatment Strategies for Patients with Early Breast Cancer
por: Agostinetto, Elisa, et al.
Publicado: (2022)

Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence
por: Rossari, José R., et al.
Publicado: (2012)

How we treat patients with metastatic HER2-positive breast cancer
por: Nader-Marta, G., et al.
Publicado: (2022)

Information perception, wishes, and satisfaction in ambulatory cancer patients under active treatment: patient-reported outcomes with QLQ-INFO25
por: Pinto, Ana Catarina, et al.
Publicado: (2014)

Lessons learned at SABCS 2019 and to-dos from immunotherapy in breast cancer
por: Eiger, Daniel, et al.
Publicado: (2020)

Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis
por: Nader-Marta, G., et al.
Publicado: (2022)

CHARACTERISTICS AND PROGNOSIS OF TRIPLE-NEGATIVE BREAST CANCER PATIENTS: A CROATIAN SINGLE INstitution RETROSPECTIVE COHORT STUDY
por: Tečić Vuger, Ana, et al.
Publicado: (2020)

The INTER-ACT E-Health Supported Lifestyle Intervention Improves Postpartum Food Intake and Eating Behavior, but Not Physical Activity and Sedentary Behavior—A Randomized Controlled Trial
por: Bijlholt, Margriet, et al.
Publicado: (2021)

Evolution of Postpartum Weight and Body Composition after Excessive Gestational Weight Gain: The Role of Lifestyle Behaviors—Data from the INTER-ACT Control Group
por: Bijlholt, Margriet, et al.
Publicado: (2021)

The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients
por: Lambertini, Matteo, et al.
Publicado: (2016)

Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer
por: Zahavi, Tamar, et al.
Publicado: (2021)

Targeted therapies in breast cancer: are heart and vessels also being targeted?
por: Criscitiello, Carmen, et al.
Publicado: (2012)

INTER-ACT: prevention of pregnancy complications through an e-health driven interpregnancy lifestyle intervention – study protocol of a multicentre randomised controlled trial
por: Bogaerts, Annick, et al.
Publicado: (2017)

Phase Angle and Bio-Impedance Values during the First Year after Delivery in Women with Previous Excessive Gestational Weight Gain: Innovative Data from the Belgian INTER-ACT Study
por: Bijlholt, Margriet, et al.
Publicado: (2021)

Influence of Ile655Val polymorphism on trastuzumab-induced cardiotoxicity in early-stage HER2 positive breast cancer
por: Vazdar, Ljubica, et al.
Publicado: (2021)

Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience
por: Franzoi, Maria Alice, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_011plbph151uatajmeivg4imqj